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(57) ABSTRACT 
The present invention provides an improved method for 
expanding cells for use in tissue engineering. In particular 
the method provides specific biochemical factors to supple- 
ment cell culture medium during the expansion process in 
order to reproduce events occurring during embryonic 
development with the goal of regenerating tissue equivalents 
that resemble natural tissues both structurally and function- 
ally. These specific biochemical factors improve prolifera- 
tion of the cells and are capable of de-differentiation mature 
cells isolated from tissue so that the differentiation potential 
of the cells is preserved. The bioactive molecules also 
maintain the responsiveness of the cells to other bioactive 
molecules. Specifically, the invention provides methods for 
expanding chondrocytes in the presence of fibroblast growth 
factor 2 for use in regeneration of cartilage tissue. 
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USE OF FIBROBLAST GROWTH FACTOR 2 
FOR EXPANSION OF CHONDROCYTES AND 
TISSUE ENGINEERING 
This application claims priority under 35 U.S.C. 119(e) 
the arovisional U.S. aaalication Ser. No. 601101.047 
entitled “Use of Growth Factors and Hormones for Expan- 
sion of Mammalian Cells and Tissue Engineering,” by 
Martin et al., filed Sep. 18, 1998 and hereby incorporated in 
its entirety by reference. 
This invention was made with U.S. government support 
under Grant Number NAG9-836 awarded by the NASA. 
The U.S. Government has certain rights in the invention. 
BACKGROUND OF THE INVENTION 
Nearly 8 million surgical procedures are performed annu- 
ally in the United States alone to treat tissue and organ 
dysfunction. Tissue engineering is the development of bio- 
logical substitutes to restore, maintain, or improve tissue 
function. Specifically, tissue engineering is a method by 
which new living tissue are created in the laboratory to 
replace diseased or traumatized tissue (Langer et al., 
Science, 260:920-926, 1993). 
One particular strategy that has been created to regenerate 
new tissue is to (i) isolate specific cells from tissue; (ii) 
expand the isolated cells in vitro; and (iii) implant the 
expanded cells into the diseased or traumatized tissue so that 
the implanted cells proliferate in vivo and eventually replace 
or repair the tissue defect (Langer et al., supra). This 
technique has been applied to a variety of cell types and 
tissue defects (for example see Brittberg et al., N. Engl. J. 
Med., 331:889-895, 1994; Rheinwald et  al., Cell, 
6:331-344, 1975; Langer et al., supra). Isolated cells could 
be either differentiated cells from specific tissues or undif- 
ferentiated progenitor cells (stem cells). In both cases, 
establishment of appropriate culture conditions for cell 
expansion is extremely important in order to maintain or 
improve their potential to regenerate structural and func- 
tional tissue equivalents (Rheinwald et al., supra) 
A particular area of focus for the development of tissue 
regeneration techniques has been correction of defects in 
cartilagenous tissue. Unlike other tissues, cartilage has little 
ability to regenerate itself after trauma, disease or as a result 
of old age. This is due to the avascular nature of normal 
articular cartilage. Although damage to the superficial chon- 
dral plate generally does not heal, the subchondral bone is 
vascularized, therefore damage to this location does heal to 
a limited degree. The new cartilage that grows in place of the 
damaged articular cartilage is called fibrocartilage. Fibro- 
cartilage lacks the durability and more desirable mechanical 
properties of the original hyaline cartilage. People who 
suffer joint damage are thereafter predisposed to arthritic 
degeneration (Freed et al., J. Biorned. Mat. Res., 28391-99, 
1994; Minas et al., Orthopedics, Jun. 20(6):525-538, 1997). 
Several different approaches have been taken to repair 
cartilage tissue. In a method utilizing cartilage explants, 
cartilage is removed from a body and cultured in vitro for 
implantation into articular cartilage defects (Sah et al., J. 
Ovthop. Res., Jan. 14 (1):44-52, 1996). Other more current 
approaches for articular cartilage repair typically consist of 
harvesting chondrocytes from cartilagenous tissue and seed- 
ing the chondrocytes directly onto a three dimensional 
transplantation matrix material before implantation of the 
replacement tissue into the damaged area (Freed et al., 
supra). This technique results in high quality cartilage once 
regeneration is complete, however this technique requires a 
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large quantity of starting material to be harvested from the 
patient, resulting in increased patient trauma. 
Chondrocytes are isolated from a biopsy, expanded in 
monolayer cultures until a sufficient number of cells are 
obtained and implanted into the damaged area of tissue. 
Implantation requires first, that the cells are either embedded 
in a gel or associated with a biodegradable polymer scaffold 
(Brittberg et al., Clin. Ovthop., May 326:270-283, 1996; 
Minas et al., supra; Freed et al., supra; ). The three dimen- 
sional nature of these matrices imparts structural integrity to 
the implant and provides rigid support for growth of the 
chondrocyte cells into cartilagenous tissue. Although this 
system has the advantage of requiring fewer cells as starting 
material, the cartilage obtained by this methods is often of 
poor quality if the cells are harvested or obtained from 
skeletally mature donors (adults). Alternatively, progenitor 
cells from the bone marrow are expanded and used to repair 
full-thickness defects involving both the articular surface 
and the underlying subchondral bone (Wakitani et al., J. 
Bone Joint Suvg, 76-A579-592,1994: Butnariu-Ephrat et 
al., Clin. Ovthop, 330:234-243, 1996). 
A distinct challenge presented by this system has been to 
increase the proliferation rate of the cells during the expan- 
sion phase in a manner that results in successful regenera- 
tion. 
There exists a need for improved expansion techniques 
for cells that are to be used in tissue engineering. 
SUMMARY OF THE INVENTION 
The present invention pertains to an improved method of 
expanding cells for use in tissue engineering. It is an aspect 
of the present invention that expanding cells in the presence 
of growth factors and hormones stimulates proliferation of 
the cell population while preserving the properties of the 
cells necessary for regenerating high quality tissue. It is 
another aspect of the present invention to provide methods 
for regenerating tissues with better structural and functional 
characteristics by recapitulating events occurring during 
embryonic development. It is yet another aspect of the 
present invention to provide methods of maintaining or 
improving the ability of the expanded cells to respond to 
differentiation stimuli as they regenerate new tissue in vitro 
or in vivo. 
The method of the present invention includes: (i) provid- 
ing a cell population; (ii) expanding the cell population in 
the presence of specific biochemical factors; and (iii) using 
the cells for tissue engineering. Avariety of cell types can be 
used in the present invention. According to the present 
invention, any cell type desirable for use in tissue engineer- 
ing that can be isolated is used to regenerate tissue. Non- 
limiting examples include endothelial cells, muscle cells, 
chondrocytes and melanocytes. Additionally, any of a vari- 
ety of biochemical factors that increase proliferation of the 
cells without losing the quality of the cell can be used in the 
process of cell expansion. Non-limiting examples of bio- 
chemical factors that may be used in the present invention 
are chondromodulins, platelet derived growth factors, epi- 
dermal growth factors, fibroblast growth factor 2, transform- 
ing growth factor beta, insulin like growth factors, bone 
morphogenetic proteins, epidermal growth factor, and plate- 
let derived growth factors. 
In a preferred embodiment of the present invention, 
cartilage tissue for tissue engineering is regenerated using 
the teachings of the present invention. The present invention 
demonstrates that chondrocytes isolated from mature carti- 
lage tissue can be expanded in the presence of fibroblast 
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growth factor-2 (FGF-2) and then used to regenerate carti- 
lage tissue. Specifically, FGF-2 added to culture medium 
during cell expansion helps the cells maintain their potential 
to regenerate cartilaginous tissue. Specifically, FGF-2 
decreases the doubling time of the cell population, while 
creating a cell  population with a homogeneous 
de-differentiated state and preserving their ability to respond 
to environmental changes such as responses to growth 
factors like insulin. 
In another preferred embodiment, chondrocytes, prefer- 
ably mammalian, and more preferably human, are isolated 
from mature cartilage tissue and expanded in vitro in the 
presence of fibroblast growth factor 2 (FGF-2) and trans- 
forming growth factor beta1 (TGFO). This expansion allows 
the de-differentiation of cells while maintaining their full 
potential for redifferentiation in response to environmental 
changes. 
In another preferred embodiment, the expansion and 
dedifferentiation of human chondrocytes results in cells that 
can be redifferentiated into primary chondrocytes for use in 
tissue engineering. Redifferentiation is performed preferably 
in a serum-free medium. More preferably, redifferentiation 
is performed in a serum-free medium containing insulin, 
transforming growth factor beta (TGFO), and dexametha- 
sone. Most preferably, redifferentiation is performed in a 
serum-free medium containing insulin, transferrin, selenous 
acid, linoleic acid, albumin, ascorbic acid, transforming 
growth factor beta (TGFO), and dexamethasone. 
In another preferred embodiment, expansion of cells in 
the presence of biochemical growth factors for use in tissue 
engineering also improves the efficiency of tranfection of 
nucleic acids into the cells. Typically, gene transfer is carried 
out during monolayer expansion. Therefore, applications 
where tissue engineering techniques are combined with gene 
therapy may be utilized in accordance with the teachings of 
the present invention. 
DEFINITIONS 
“De-differentiation”: “De-differentiation’’ is used herein 
to describe cells that lack differentiated functions and to 
imply regression to an earlier bipotent or multipotent embry- 
onic state. For example, when chondrocytes from cartilage 
tissue are released from the cartilage matrix and placed in a 
monolayer culture, they stop producing characteristic mark- 
ers that define them as being differentiated. Two such 
markers for differentiated chondrocyte cells are two well 
characterized structural macromolecules, cartilage pro- 
teoglycan and type I1 collagen. 
“Bioactive molecule” or “biochemical factor”: “Bioactive 
molecule” or “biochemical factor” is used herein to refer to 
any chemical or protein that can elicit any metabolic 
response from a cell. A biochemical factor can be a protein, 
for example a hormone or a growth factor that will stimulate 
a specific biochemical pathway in the cell. A biochemical 
factor can also be a simple chemical such as a chemothera- 
peutic agent. “Bioactive molecule” is also encompassing of 
any hydrodynamic factor or signal. 
“Expand”: “Expanding”, “expanded”, or expand is used 
herein to refer to the process or growing cells in vitro. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1A is a graph representing the weight of the engi- 
neered construct grown from either primary chondrocytes or 
chondrocytes expanded with or without FGF-2 in the pres- 
ence or absence of insulin. 
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FIG. 1B is a graph representing the percent wet weight of 
glycosaminoglycan of constructs grown from either primary 
chondrocytes expanded with or without FGF-2 in the pres- 
ence or absence of insulin. 
FIG. 2. Collagen type I1 stain of chondrocyte monolayers. 
Chondrocytes expanded without (A, C) or with (B, D) 
FGF-2 after the first (A, B) and second (C, D) passage. 
FGF-2-expanded chondrocytes displayed lower levels of 
type I1 collagen, suggesting faster and more homogeneous 
FIG. 3 (Panels A-D). F-actin stain of chondrocyte mono- 
layers. Chondrocytes expanded for two passages in medium 
without FGF-2 (A), with (B) FGF-2, and in medium with 
FGF-2 only during the first passage (C) or only during the 
second passage (D). Chondrocytes expanded without FGF-2 
displayed thick F-actin fibers. Scale bar=lO pm. 
FIG. 4 (Panels A-F). Glycosaminoglycan (GAG) and 
collagen type I1 stain of chondrocyte-polymer constructs. 
Constructs based on primary chondrocytes (I), and chon- ’’ drocytes expanded for two passages without FGF-2 (11) and 
with FGF-2 (111), after 1 week (A,B,C) and 6 weeks (D,E,F) 
of cultivation. Histological sections were stained with Saf- 
ranin 0 for GAG (A,B,D,E) or with a monoclonal antibody 
to type I1 collagen (C,F). Primary and FGF-2-expanded ’’ chondrocytes deposited a continuous ECM containing high 
concentrations of GAG and type I1 collagen, while chon- 
drocytes expanded without FGF-2 induced contraction of 
the polymer scaffold and resulted in constructs with low 
amounts of GAG and non detectable amounts of type I1 
30 collagen. Arrows indicate polymer fibers. Scale bar=2 mm 
(A,D) or 100 pm (B,C,E,F). 
FIG. 5 (Panels A-C). F-actin stain of chondrocyte- 
polymer constructs. Constructs based on primary chondro- 
35 cytes (A), and chondrocytes expanded for two passages 
without FGF-2 (B) and with FGF-2 (C), cultured for 1 week. 
Primary and FGF-2 expanded cells had a spherical morphol- 
ogy typical of differentiated chondrocytes, while cells 
expanded without FGF-2 had an elongated, fibroblast-like 
4o appearance, with abundant F-actin structures in the cyto- 
plasm. Arrow indicates a residual polymer fiber. Scale 
bar=20 pm. 
DETAILED DESCRIPTION OF THE 
INVENTION 
5 
10 dedifferentiation. Scale bar=100 pm. 
45 Cells to Be Implanted 
The present invention provides improved methods of 
tissue engineering. In particular, the invention provides 
improved approaches to expanding cells for use in tissue 
engineering applications. The basic theory underlying the 
SO present invention is that in order to regenerate tissues with 
better structural and functional characteristics, it is desirable 
to recapitulate events occurring during embryonic develop- 
ment. In one preferred embodiment, cells isolated from a 
mature tissue are expanded and de-differentiated in the 
ss presence of specific biochemical factors in order to preserve 
their differentiation potential. In this way, the cells may be 
better able to respond to differentiation stimuli when they 
regenerate new tissue in vitro or in vivo. 
Specifically, the present invention provides methods for 
60 improved expansion of various cell types that can be used in 
tissue engineering. In one preferred embodiment, the present 
invention provides growth factors to the cell culture medium 
to promote proliferation of the cells while maintaining the 
differentiation potential of the cells. To give but a few 
65 examples, growth factors that can be used in the present 
invention include chondromodulins, platelet derived growth 
factors, epidermal growth factors, heparin binding factor, 
US 6,582,960 B3 
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transforming growth factor alpha and beta, alpha fibroblastic growth environment of the cells during in vitro expansion of 
growth factor, fibroblast growth factor 2, insulin like growth cells preferably promotes optimization of the expansion 
factors, bone morphogenetic proteins, and vascular endot- process. In the present invention, it is preferable that the 
helium growth factor. In another embodiment, the invention expanded cells are homogeneous with respect to their stage 
provides hormones (e.g., insulin glucagon or estrogen) to the 5 of differentiation. According to the present invention, the 
cell culture medium to promote proliferation of the cells growth environment may be manipulated by the addition of 
while maintaining the differentiation potential of the cells. In growth factors and/or hormones to achieve a homogeneous 
still other preferred embodiments, angiogenic factors may population of de-differentiated cells. 
be used for in vitro expansion. In a particularly preferred embodiment, chondrocytes are 
Those of ordinary skill in the art will appreciate the expanded by the methods of the present invention for the 
variety of cell types to which this method of cell expansion regeneration of cartilage tissue. Specifically, chondrocytes 
can be applied. Tissue engineering techniques have been isolated from a subject are expanded in the presence of 
used to correct defects in a myriad of different cell types. growth factors that increase the proliferation rate of the 
Tissue engineering can be applied to the correction of hard chondrocytes while preserving the appropriate differentia- 
tissue defects, such as defects in cartilage or bone that arise tion properties of the cells to ensure successful regeneration 
from disease or trauma. Tissue engineering has also been of high quality cartilage tissue for implantation. 
applied to the correction of soft tissue structures. By way of Prior to the present invention, cartilage tissue was main- 
example, cells used in the current invention can be used to tained in tissue culture one of two ways: (i) cartilage tissue 
regenerate metabolic organs (e.g., the liver or pancreas), was isolated from the body and propagated in in vitro tissue 
epidermal tissue (e.g., of burn victims) or to reconstruct or culture (tissue explant), or (ii) primary chondrocyte cells 
augment breast tissue (e.g., muscle cells may be used to 20 isolated from cartilage tissue were seeded onto a three 
reconstruct the breast of women afflicted with breast cancer, dimensional polymeric scaffold and allowed to proliferate 
congenital defects, or damage resulting from trauma; see and differentiate on the scaffold to form cartilage tissue 
U.S. Pat. No. 5,512,600 and W0196118424, both of which (tissue implants). Efforts to first expand the chondrocyte 
are incorporated herein by reference). Furthermore, con- cells in in vitro monolayer cultures, prior to seeding the three 
genital defects such as vesicoureteral reflux, or incontinence zs dimensional polymeric scaffold were generally unsuccessful 
can be corrected by implantation of a gel or scaffolding in that the cartilage tissue obtained from such efforts was of 
matrix seeded with muscle cells in an effective amount to poor quality compared to the cartilage tissue obtained by 
yield a muscle area that provides the required control over seeding the polymeric scaffold with freshly isolated primary 
the passage of urine or otherwise corrects the defect (U.S. chondrocytes. 
Pat. No. 5,667,778; incorporated herein by reference). It is known that mammalian cells (e.g., chondrocytes and 
According to the present invention, the cells used to bone) in a three dimensional environment respond very 
reconstruct or augment the specific physical location can be differently to stimuli (e.g., biochemical factors and hydro- 
different from the cells that normally constitute that tissue in dymanic factors or signals) than do cells in monolayer 
the body. For example, chondrocytes can be used to correct cultures. It has been demonstrated that the differentiated 
soft tissue defects by serving as a bulking agent (U.S. patent 35 phenotype of chondrocyte cells can be stabilized by trans- 
application, Ser. No. 081654,844, Now U.S. Pat. No. 6,060, ferring them from a monolayer culture into a three dimen- 
053). In certain preferred embodiments, multiple cell types sional environment (Benya et al., Cell, 30:215-224, 1982; 
are used to create a single regenerated tissue. In each case, incorporated herein by reference). Chondrocyte cells in 
it is important that the cells of the present invention are monolayer culture typically form differentiated fibroblast 
expanded and de-differentiated in the presence of specific 40 cells (Kato et al., J .  Cell Biol., February, 100(2):477-485, 
biochemical factors, without losing the cellular properties 1985). This loss of the chondrocytic phenotype in monolayer 
required for successful tissue regeneration. culture contributes to the inability of expanded cells to 
Many different biochemical factors can be used in the successfully seed and regenerate cartilage tissue that is 
present invention. Specific biochemical factors are prefer- equivalent to cartilage tissue formed by freshly isolated 
ably able to stimulate proliferation of the relevant cells in 45 primary chondrocytes directly seeded onto the polymeric 
vitro and are able to promote de-differentiation of differen- matrix. A particular challenge is to increase the cell mass 
tiated cells isolated from mature tissue. According to the without losing the quality of the cell and thus also the 
present invention, a factor that, when added to tissue culture resulting regenerated cartilage tissue. 
medium during expansion of the isolated cells, decreases the Fibroblast growth factor (FGF-2) has been applied in vitro 
doubling time of that cell population is preferred. The SO to chondrocyte cells both in monolayer culture and in three 
present invention also provides factors that, when added to dimensional environments. It has been established that 
tissue culture medium have the effect of reversing the fibroblast growth factor 2 (FGF-2) (also called basic fibro- 
differentiation process of a particular mature cell type, or blast growth factor) is a potent mitogen for chondrocytes in 
maintaining the differentiation potential of an immature cell monolayer culture and in vivo (Wroblewski et al., J .  Bone 
type. Particularly preferred are biochemical factors that both ss Miner: Res., May, 10(5):735-742, 1995; Kat0 et al., J .  Biol. 
decrease the doubling time of the particular cell population Chem., 265:5903-5909, 1990), However, reports about the 
and preserve the differentiation potential. Such characteris- use of FGF-2 to culture cartilage tissue in vitro in a three 
tics reproduce an embryonic environment for the cell and dimensional environment have been contradictory. For 
promote regeneration of quality tissue for such applications example, FGF-2 has been reported both (i) cause a waning 
as described above. Without wishing to limit the invention, 60 of the mature phenotypic characteristics typical of cartilage 
some examples of biochemical factors that can be used in the explants (Sah et al., supra), and (ii) increase the rate of 
present invention are chondromodulins, platelet derived proliferation without affecting the mature phenotypic char- 
growth factors, epidermal growth factor, fibroblast growth acteristics of chondrocyte-seeded implants in the presence of 
factor 2, transforming growth factor beta, insulin like growth FGF-2 (Toolan et al., J .  Biomed Muter Res., June 31(2): 
The condition of the expanded cells significantly affects Although chondrocytes have been cultured in the pres- 
the successful regeneration of quality tissue. Therefore, the ence of FGF-2, and FGF-2 has been used to culture chon- 
30 
factors, and bone morphogenetic proteins. 65 273-280, 1996). 
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drocyte seeded implants, FGF-2 expanded chondrocytes ence of FGF-2 are responsive to insulin in a manner similar 
have not previously been used for tissue engineering or to chondrocytes harvested directly from cartilage tissue and 
regeneration. Given the varied effects FGF-2 has on chon- seeded directly onto the implantation matrix without an 
drocytes in monolayer cultures versus on polymeric intervening expansion step (see Example 1). Since FGF-2 
scaffold, there was no reasonable expectation that using cells s expanded chondrocytes are highly responsive to insulin in a 
expanded in FGF-2 to seed three dimensional matrices similar fashion as freshly harvested chondrocytes, they 
would be successful. might represent an appropriate cell population for cartilage 
The present invention pertains to the use of FGF-2 as a regeneration in those therapies involving the use of addi- 
culture medium supplement in order to optimize in vitro tional hormones and growth factors to further stimulate 
expansion of mammalian chondrocytes. The present inven- i o  tissue regeneration. 
tion demonstrates that when FGF-2 is added to the culture Generally, it is preferred that any cell type used in the 
medium during the expansion phase, not only do chondro- practice of the present invention be able to receive and 
cytes proliferate faster, but they also retain a higher potential respond to environmental stimuli present in vitro or in vivo 
to regenerate cartilaginous tissue equivalents (see Example during the process of tissue regeneration. Preferably the cells 
1). Faster proliferation also decreases the initial amount of is are heterologous cells. Alternatively, the cells are isolated 
tissue needed and/or the time required to obtain a sufficient from a close relative or from an individual of the same 
amount of cells to seed onto a scaffold or gel structure. species. It will be appreciated by those of ordinary skill in 
Without wishing to be bound by any particular theory, we the art that a cell population that is responsive to prolifera- 
propose that FGF-2 is effective not in inducing chondro- tion or differentiation cell stimuli will be advantageous for 
genic differentiation of regenerating tissue, but in preserving 20 use in tissue engineering. A cell population that can respond 
the chondrogenic differentiation potential of chondrocytes better to such stimuli will regenerate more quickly, more 
during their in vitro expansion of chondrocyte cells. These dependably and as a result yield a higher quality tissue for 
results suggest that expansion of chondrocytes in medium implantation. In certain embodiments of the present 
containing FGF-2 helps preserve their potential to regener- invention, it is desirable to add bioactive molecules to the 
ate cartilaginous tissue. Therefore, chondrocytes expanded zs cells during the regeneration process. A variety of bioactive 
with FGF-2 represent a cell population with a higher poten- molecules can be delivered using, for example, matrices 
tial for repairing cartilage defects than chondrocytes described in U.S. Pat. No. 5,716,404 (see below). In one 
expanded in culture medium lacking FGF-2. It is particu- particularly preferred embodiment of the present invention, 
larly preferred that chondrocytes are expanded in the pres- FGF-2 is used to improve expansion of various cell types 
ence of FGF-2 prior to seeding an implantation matrix at 30 (e.g., endothelial cells, muscle cells, melanocytes, 
which time further proliferation on the matrix can be per- hepatocytes, mesenchymal stem cells). 
formed in the presence or absence of FGF-2. In another preferred embodiment, proteins other than 
In another preferred embodiment of the present invention, FGF-2 (e.g., chondromodulins) are used to further improve 
mammalian chondrocytes, preferably human, are expanded chondrocyte expansion. Any bioactive molecule that 
in a medium containing fibroblast growth factor-2 (FGF-2) 3s improves the proliferation, differentiation potential or qual- 
and preferably also containing transforming growth factor ity of the resulting regenerated tissue can be used according 
beta (TGFO). As previously discussed, expansion of chon- to the present invention. 
drocytes in cell culture medium allows the de-differentiation In yet another preferred embodiment, expansion of cells 
of cells while maintaining their full potential for redifferen- in the presence of biochemical growth factors for use in 
tiation in response to environmental changes and produces 40 tissue engineering also improves the efficiency of tranfection 
cells that are useful for regenerating cartilage through tissue of nucleic acids into the cells. Typically, gene transfer is 
engineering. carried out during monolayer expansion. Therefore, appli- 
Furthermore, human chondrocytes expanded in a cell cations where tissue engineering techniques are combined 
culture medium containing FGF-2and TGFO are preferen- with gene therapy may be utilized in accordance with the 
tially redifferentiated into primary chondrocytes in a cell 4s teachings of the present invention. For example without 
culture medium substantially free of serum. Preferably, the limitation, cells may be transfected with a vector which 
serum-free cell culture medium also contains insulin, TGFO confers resistance to a variety of biological and chemical 
and dexamethasone. Even more preferably, the serum-free compounds. These compounds include but are not limited to 
cell culture medium contains insulin, transferrin, selenous antibiotics, cytokines and inflammatory agents. 
acid, linoleic acid, albumin, ascorbic acid, transforming SO Implantation 
growth factor beta (TGFO), and dexamethasone. Experi- Dissociated cells are implanted in combination with suit- 
ments described in Example 2 demonstrate that human able biodegradable, polymeric matrix to form new tissue. 
chondrocytes that are expanded in cell culture medium in There are two forms of matrices which can be used: a 
monolayers to induce the highest proliferation rate, subse- polymeric hydrogel formed of a material such as alginate 
quently produce the highest levels of redifferentiation mark- ss having cells suspended therein, and a fibrous matrix having 
ers if expanded in the presence of TGFO and FGF-2. an interstitial spacing between about 100 and 300 microns. 
Furthermore, redifferentiation of expanded human chondro- Preferred polymeric matrices are those degrading over about 
cytes produces the highest levels of differentiation markers one to two months, such as polylactic acid-glycolic acid 
if cultured in a serum-free cell culture medium containing copolymers. The matrices can be seeded prior to implanta- 
insulin, TGFO and dexamethasone. 60 tion or implanted, allowed to vascularize, then seeded with 
In another aspect of the present invention, it is desirable cells. For a detailed description of hydrogel polymer solu- 
that cells prepared for seeding implantation matrices be tions and polymeric matrices, and other methods of implan- 
responsive to other biochemical factors and signals. Chon- tation see U.S. Pat. No. 5,716,404, incorporated herein by 
drocytes freshly isolated from cartilagenous tissue are nor- reference. For other methods of using biodegradable poly- 
mally responsive to insulin which causes increased prolif- 65 mers to regenerate metabolic organs and other tissues, for 
eration of the chondrocytes. The present invention example cartilage see Cima et al., Biotechn. Bioeng., 
demonstrates that chondrocytes first expanded in the pres- 38: 145-158, 1991; Langer et al., Biomatevials, 11:738-745, 
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1990; Vacanti et al., J.  Pediatr: Suvg., 23:3-9, 1988; and comparable to that in constructs based on FGF-2 expanded 
Vacanti et al., Arch. Suvg., 123:545-549, 1988, all of which chondrocytes, and significantly higher than that in constructs 
are incorporated herein by reference. based on chondrocytes expanded in control medium. The 
implanted in combination with tissue expander devices. As s culture medium (FIG. 1B). Collagen type 11 was d ~ n d a n t  in 
the cell-matrix is implanted, or cells proliferate and form constructs based O n  Primary and FGF-2 
new tissue, the expander size is decreased, until it can be chondrocytes, and not detectable if cells where expanded 
removed and the desired reconstruction or augmentation is without FGF-2. 
The presence of FGF-2 during chondrocyte expansion obtained. increased the proliferation rate during the first passage As previously mentioned, other materials, such as bioac- i o  (Table 1) and accelerated the process of dedifferentiation, as tive molecules that enhance vascularization of the implanted assessed by the reduced expression of Ap (Table 1) and 
tissue and/or inhibit ingrowth of fibrotic tissue, can be collagen type II (FIG, 2), Ap activity decreased with serial 
implanted with the matrix to enhance development of more passage and at a rate that was higher in the presence of 
normal tissue. FGF-2 (Table 1). Collagen type I1 was generally detected in 
the P1 chondrocytes, but the fraction of cells that were positive 
following Examples, which are not meant to limit the scope and the intensity of the stain were both higher for cells 
of the invention. Other aspects, advantages, and mdifica- expanded without FGF-2 (FIGS. 2A and 2B). Collagen type 
tions within the scope of the invention will be apparent to 11 was expressed by only a few p2 cells expanded without 
those skilled in the art to which the invention pertains. The FGF-2 (FIG. 2C), and was not detected in any P2 cells 
following examples are intended to provide those of ordi- 20 expanded with FGF-2 (FIG. 2D). Collagen type I was 
nary skill in the art with a complete disclosure and descrip- expressed at similar levels in cells expanded with or without 
tion of how to make and use the novel methods of the FGF-2 (data not shown). 
invention, and are not intended to limit the scope of what the ChondrocYtes expanded without FGF-2 displayed long, 
inventors regard as their invention in any way. thick F-actin fibers, which were particularly evident after the 
2s second passage (FIG. 3A), while chondrocytes expanded in 
EXAMPLES the uresence of FGF-2 exhibited diffuse labeling for F-actin 
Example 1 
Use of FGF-2 in the Optimization of in vitro Expansion of 
Mammalian Chondrocytes 
Results demonstrate that if FGF-2 is added to the culture 
medium during the expansion phase, not only do chondro- 
cytes proliferate faster, which decreases the initial amount of 
tissue needed and/or the time required, but also they retain 
a higher potential to regenerate cartilaginous tissue equiva- 
In Some embodiments, the cell-matrix structures are same trend was observed when insulin was added to the 
The Present invention now be 
30 
(FIG. 3B). In addition, chondrocytes that were expanded 
with FGF-2 during only the first passage and not the second 
passage developed thick F-actin fibers (FIG. 3C), while 
chondrocytes expanded without FGF-2 during the first pas- 
sage and then with FGF-2 during the second passage showed 
a diffuse cytoplasmic staining for F-actin (FIG. 3D). Large, 
spread cellular morphology appeared to correlate with the 
presence of thick F-actin fibers (FIG. 3). 
lents. 3s Example 2 
Bovine articular chondrocytes were expanded in mono- Expansion of Human Chondrocytes 
layers. By the addition of 5 ngiml FGF-2 to the culture Human chondrocytes were isolated from hip and ankle 
medium, the proliferation rate was significantly increased articular surfaces of 25 to 66 year old patients undergoing 
(doubling times were 13.920.6 and 18.921.0 hours for cells join replacement following femoral neck fracture or soft 
expanded with and without FGF-2, respectively). Bovine 40 tissue tumor resection. Cells were expanded in monolayers 
chondrocytes, expanded by approximately 10 doubling with for 16 days (2 passages, approximately 5-9 doublings) in 
and without FGF-2 (5 ngiml), as well as freshly harvested DMEM containing 10% FBS, and supplemented with FGF- 
primary chondrocytes, were seeded onto biodegradable 2, transforming growth factor-01 (TGF0, epidermal growth 
polymer scaffolds (nonwoven meshes made of a poly factor (EGF), platelet-derived growth factor-bb (PDGF), or 
(glycolic acid), PGA) as previously described (Freed et al., 4s a combination of TGF0 and FGF-2 (T+F). The doubling 
supra). The resulting cell-polymer constructs were cultured times of chondrocytes were derived as described above. 
in medium containing 10% fetal bovine serum, without After each passage, the expression of specific genes 
(control) or with the addition of 5 ngiml insulin. FGF-2 was (collagen type I and 11, aggrecan and versican) was inves- 
not supplemented to the culture medium in any group at this tigated at transcriptional level using real-time, quantitative 
stage. After 6 weeks in culture, constructs were blotted dry, SO PCR assays based on TaqMan fluorescence. The degree of 
weighed and assessed biochemically for the content of differentiation was assessed as the ratio of collagen type I1 
glycosaminoglycans (GAG; FIG. l ) ,  one of the main com- to type I1 (CIIICI) or aggrecan to versican (AGGIVER) at 
ponent of cartilage extracellular matrix. Duplicate samples the mRNA level. Primary and P2 chondrocytes, expanded 
were processed histologically and stained for collagen type with and without FGF-2, were seeded on PGA meshes, 
I1 (FIGS. 2 and 4). ss cultured and assessed as described above for bovine chon- 
FGF-2 expanded chondrocytes were able to regenerate drocytes. Primary and P2 chondrocytes, expanded in the 
cartilaginous constructs that were significantly larger in size presence of the different factors tested, were also centrifuged 
than those based on chondrocytes expanded in control in polypropylene conical tubes to form spherical pellets 
medium and approached the size of constructs based on (5x10' cellsipellet). Pellets were cultured for 2 weeks either 
freshly harvested chondrocytes (FIG. 1A). The addition of 60 in DMEM containing serum and insulin, or in a defined 
insulin to the culture medium induced a significant increase (serum-free) medium, consisting of DMEM containing 
in the final weight of the constructs based on freshly insulin, TGF0 and dexamethasone. Pellets were assessed 
harvester chondrocyte s and on FGF -2 expanded histologically, biochemically, and using quantitative PCR. 
chondrocytes, while chondrocytes expanded in control Duplicate samples from three independent experiments were 
medium were not significantly responsive to insulin. 65 analyzed. 
The GAG fraction (percentage of construct wet weight) in Of all the factors tested during the expansion phase in 
constructs based on freshly harvested chondrocytes was monolayers, FGF-2 was the one that most increased the 
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proliferation rate of human chondrocytes, in particular if 
used in combination with TGFfl(doub1ing times for cells 
cultured in control, FGF-2 and TGFfl+FGF-2 supplemented 
media were 76.623.9, 47.422.0 and 38.222.9 hours, 
respectively). Cell proliferation rate was inversely related to 5 
the stage of differentiation. P2 chondrocytes expanded under 
control conditions had CIIiCI and AGGiVER ratios averag- 
expansion, and these ratios were further reduced to 0.3% and 
0.002% if cells were expanded in the presence of FGF-2 or 
TGFfl+FGF-2, respectively. The redifferentiation of sufficient to de-differentiate the differentiated cells; 
spective of the conditions of cell expansion, CIIiCI ratios 
were approximately 4 fold higher if pellets were cultured in 
defined medium, as opposed to medium containing serum. 
based on TGFfl+FGF-2(CTR). In TGFfl+FGF-2 pellets, harvested cells, wherein the differentiated cells are 
CIIiCI and AGGNER ratios were respectively 50 and 3 fold human chondrocyte cells. 
higher than in CTR pellets, and both ratios were as high as 4. Amethod of generating tissue comprising the steps of: 
50% of those measured in pellets based on primary chon- (i) providing differentiated cells in a cell culture medium 
drocytes. 20 comprising fibroblast growth factor 2 in an amount 
The results have demonstrated that chondrocytes sufficient to de-differentiate the differentiated cells; 
expanded under the conditions inducing the highest prolif- (ii) de-differentiating the differentiated cells and expand- 
eration rate and the most enhanced dedifferentiation were 
those displaying the best ability to re-enter the differentia- 
tion program when transferred into a 3D environment. In 25 (iii) harvesting the expanded 
particular, the serially passaged bovine chondrocytes cul- 6.1 generating a tissue in Vivo Or ex Vivo using the 
tured on PGA meshes regenerated cartilaginous tissues at harvested cells, wherein the differentiated cells are 
rates and to degrees comparable to those observed for bovine chondrocyte cells. 
primary chondrocytes only if expanded in the presence of 5 .  The method of claim 1, wherein the cell culture 
FGF-2. In addition, serially passaged adult human chondro- medium comprises fibroblast growth factor 2 in an amount 
cytes cultured in defined medium as pellets expressed the sufficient to maintain or induce an ability of the cells to 
highest levels of differentiation markers, approximately 50% respond to differentiation stimuli. 
of the levels measured for primary chondrocytes, if 6. The method of claim 1, wherein the cell culture 
expanded in the presence of TGFfl and FGF-2. medium comprises fibroblast growth factor 2 in an amount 
sufficient to decrease doubling time of the cells. 
TABLE 1 7. The method of claim 1, wherein the step of 
(ii) de-differentiating the differentiated cells and expand- 
(iii) harvesting the expanded cells; and 
(iv) generating a tissue in vivo or ex vivo using the 
harvested cells, wherein the differentiated cells are 
mammalian chondrocyte cells. 
ing the de-differentiated cells; 
ing 2% of those measured in primary chondrocytes before 3. A method Of generating tissue comprising the steps Of: 
(i) providing differentiated cells in a cell culture medium 
comprising fibroblast growth factor 2 in an amount 
expanded chondrocytes in pellet cultures showed that, irre- (ii) &-differentiating the differentiated cells and expand- 
ing the de-differentiated cells; 
(iii) harvesting the expanded cells; and 
The highest extent of differentiation was detected in pellets 15 (iv> generating a tissue in Or ex the 
ing the de-differentiated cells; 
and 
30 
3s  
Doubling times and alkaline ph( 
chondrocytes in 
de-differentiating the chondrocyte cells and expanding the 
de-differentiated cells further comprises transfecting the 
cells with nucleic acids. 
xphatase (AP) activities of 
monolavers. 
Doubling time AP activity 8. A method of generating cartilaginous tissue comprising 
(i) providing chondrocyte cells in a cell culture medium 
comprising fibroblast growth factor 2 in an amount 
sufficient to de-differentiate the chondrocyte cells; 
P2 45 (ii) de-differentiating the chondrocyte cells and expanding 
the de-differentiated cells: 
Group (hours) (% of primary chondrocytes)a 40 the steps o f  
- P1 
-FGF-2 18.9 r 1.0 45.0 r 7.4 
+FGF-2 13.9 r 0.6* 26.7 r 0.9* 
- 
(iii) harvesting the expanded cells; and 
(iv) generating a cartilaginous tissue in vivo or ex vivo 
-FGF-2 13.6 r 2.2 9.7 r 1.6 
+FGF-2 12.4 r 1.2 7.8 r 0.3 
~ I -  
aAP activity of primary chondrocytes averaged 17.2 r 0.4 Unitsirnillion 
(-FGF-2) 
using the harvested cells. 
cells 
*Statistically significant difference from the corresponding control group 9' The method Of 8 2  wherein the step Of providing 
chondrocyte cells comprises providing mammalian chon- 
drocyte cells. 
10. The method of claim 8, wherein the step of providing We claim: 
(i) providing differentiated cells in a cell culture medium 55 cells, 
'. A method Of generating tissue comprising the steps Of: chondrocyte cells comprises providing human chondrocyte 
comprising growth factor in an amount 11, The method of claim 8, wherein the step of providing 
sufficient to de-differentiate the differentiated cells; 
(ii) de-differentiating the differentiated cells and expand- 
ing the de-differentiated cells; 
(iii) harvesting the expanded cells; and 
(iv) generating a tissue in vivo or ex vivo using the 
harvested cells, wherein the differentiated cells are 
chondrocyte cells. 
2. A method of generating tissue comprising the steps of: 
(i) providing differentiated cells in a cell culture medium 65 sufficient to decrease doubling time of the cells. 
chondrocyte cells comprises providing bovine chondrocyte 
cells, 
12. The method of claim 8, wherein the cell culture 
60 medium comprises fibroblast growth factor 2 in an amount 
sufficient to maintain or induce an ability of the cells to 
respond to differentiation stimuli. 
13. The method of claim 8, wherein the cell culture 
medium comprises fibroblast growth factor 2 in an amount 
comprising fibroblast growth factor 2 in an amount 14. The method of claim 8, wherein the step of 
sufficient to de-differentiate the differentiated cells; de-differentiating the chondrocyte cells and expanding the 
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de-differentiated cells further comprises transfecting the 
cells with nucleic acids. 
15. A method of generating cartilaginous tissue compris- 
ing the steps of  
17. The method of claim 15 wherein the chondrocyte cells 
18. The method of claim 15, wherein the chondrocyte 
19. The method of claim 15, wherein the cell culture 
sufficient to maintain or induce an ability of the cells to 
respond to differentiation stimuli. 
20. The method of claim 15, wherein the cell culture 
medium comprises fibroblast growth factor 2 in an amount 
21. The method of claim 15, wherein the step of 
de-differentiating the chondrocyte cells and expanding the 
de-differentiated cells further comprises transfecting the 
cells with nucleic acids. 
comprise human chondrocyte cells. 
cells comprise bovine chondrocyte cells. 
(i) providing chondrocyte in a in a ’ medium comprises fibroblast growth factor 2 in an amount 
culture medium comprising fibroblast growth factor 2 
in an amount sufficient to de-differentiate the chondro- 
cyte cells; 
(ii) de-differentiating the chondrocyte cells and expanding 
the de-differentiated cells; 
(iii) harvesting the expanded cells; and 
(iv) generating a tissue in vivo or ex vivo using the 
16. The method of claim 15, wherein the chondrocyte 
IO sufficient to decrease doubling time of the cells. 
harvested cells. 
cells comprise mammalian chondrocyte cells. * * * * *  
